• / Free eNewsletters & Magazine
  • / My Account

High Risk

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Credit Suisse unit fined over deficiencies in its anti-money-laundering program

    Credit Suisse unit fined over deficiencies in its anti-money-laundering program

  2. New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High -Risk Myelodysplastic Syndrome

    New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High - Risk Myelodysplastic Syndrome

  3. Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

    Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

  4. Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)

    Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)

  5. Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL

    Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL

  6. Asbestos Disease Awareness Org. President Commends the EPA For Taking Life-Saving Action by Prioritizing Asbestos Regulation Under the Lautenberg Act

    Asbestos Disease Awareness Org. President Commends the EPA For Taking Life-Saving Action by Prioritizing Asbestos Regulation Under the Lautenberg Act

  7. Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD

    Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD

  8. UPDATE: What to expect from HHS Secretary nominee and Obamacare opponent Tom Price

    UPDATE: What to expect from HHS Secretary nominee and Obamacare opponent Tom Price

  9. UPDATE: What to expect from Tom Price, President-elect Trump's pick for HHS Secretary

    UPDATE: What to expect from Tom Price, President-elect Trump's pick for HHS Secretary

  10. Plans to Repeal & Replace Obamacare: eHealth Answers Questions About Proposals by President-Elect Trump’s Nominee for Secretary of Health and Human Services, Representative Tom Price, MD

    Plans to Repeal & Replace Obamacare: eHealth Answers Questions About Proposals by President-Elect Trump’s Nominee for Secretary of Health and Human Services, Representative Tom Price, MD

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.